NeoGenomics, Inc. Stock News

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York.

Those subscribing to a momentum investing strategy tend to believe that stocks experiencing price increases tend to rally, so long as both internal and external conditions don't change. Of course, no rally can continue forever, so investors may measure momentum across different timeframes.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes.

NeoGenomics' recent 32.23% stock price decline post-Q1 earnings miss is seen as a buying opportunity due to overreaction and long-term growth potential. Despite a slight revenue miss, the company's long-term growth remains strong, with a 10-year CAGR of 23.27% and a positive future outlook. The company's acquisition of Pathline and raised FY 2025 guidance further support its growth and underval...

NeoGenomics, Inc (NASDAQ:NEO ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Tony Zook - Chief Executive Officer Warren Stone - President and Chief Operating Officer Andrew Lukowiak - Chief Innovation Officer Jeffrey Sherman - Chief Financial Officer Kareem Saad - Head, Strategy and Transformation Ali ...

FORT MYERS, Fla. and FREMONT, Calif.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced analytical validation of its PanTracer LBx™ assay, to be presented with five other abstracts at the AACR Annual Meeting 2025.